Table 1 Patient demographics (SAS)
Demographic variable | Pazopanib N = 190 |
|---|---|
Age, years | |
Mean (SD) | 61.2 (12.3) |
Median (range) | 61.0 (22.0–96.0) |
Age category, n (%) | |
≥ 65 years | 71 (37.4) |
Sex, n (%) | |
Male | 133 (70.0) |
Race, n (%) | |
Caucasian | 55 (28.9) |
Black | 2 (1.1) |
Asian | 133 (70.0) |
BMI, kg/m2, n = 120 | |
Mean (SD) | 24.8 (5.1) |
Median (range) | 23.9 (14.1–41.9) |
Disease status, n (%) | |
Metastatic | 182 (95.8) |
Locally advanced | 8 (4.2) |
Predominant histology/cytology, n (%) | |
Clear cell carcinoma | 153 (80.5) |
Non-clear cell carcinoma | 18 (9.5) |
Papillary | 12 (6.3) |
Chromophobe | 3 (1.6) |
Invasive ductal carcinomaa | 1 (0.5) |
Unknown non-clear cell carcinomab | 2 (1.1) |
Missing | 2 (1.1) |
Otherc | 17 (8.9) |
MSKCC prognostic, n (%) | |
Favourable | 17 (8.9) |
Intermediate | 90 (47.4) |
Poor | 19 (10.0) |
Unknown | 64 (33.7) |
IMDC prognostic, n (%) | |
Favourable | 15 (7.9) |
Intermediate | 80 (42.1) |
Poor | 22 (11.6) |
Unknown | 73 (38.4) |
Common (≥ 20%) site of metastases, n (%) | |
Lung | 126 (66.3) |
Lymph node | 74 (38.9) |
Bone | 52 (27.4) |
Liver | 37 (19.5) |
Number of metastatic sites, n (%) | |
0 | 8 (4.2) |
1 | 62 (32.6) |
2 | 69 (36.3) |
3 | 29 (15.3) |
> 3 | 22 (11.6) |
Prior antineoplastic surgeries reported, n (%) | 143 (75.3) |
Prior antineoplastic medications reported, n (%) | 14 (7.3) |
Duration of prior antineoplastic medications, months, mean (SD) | 3.7 (4.3) |